Life Technologies and Sino Biological sign strategic partnership agreement

Life Technologies Corporation, a US-based global biotechnology company, and Sino Biological, a Chinese biotech company, have announced a partnership for worldwide product distribution and product development. Life Technologies will distribute Sino Biological’s portfolio of recombinant proteins, antibodies and ELISA kits through its global distribution channels.

The two companies will also jointly develop new products, leveraging R&D synergies to introduce innovative products more quickly. By partnering with one another, the companies are well positioned to provide proteomics products to a global customer base and contribute to accelerating growth of the Chinese biotech industry.

“The collaboration presents a tremendous opportunity to offer a robust proteomics portfolio to meet customer needs in this highly dynamic global market,” said Gregory T Lucier, Chairman and CEO of Life Technologies. “Through this collaboration we plan to leverage our strong brands, worldwide commercial reach and technology support with Sino Biological’s world-leading technologies to develop solutions for scientists worldwide who are tackling important healthcare challenges such as cancer, diabetes and heart disease.”

“Sino Biological’s mission is to develop the best quality biological tools to assist scientists,” said Dr Liangzhi Xie, President and CEO of Sino Biological. “Combining our state-of-the-art, disruptive technologies in recombinant protein production and antibody development with Life Technologies’ innovative product development and worldwide marketing will allow us to bring powerful research tools to scientists solving critical puzzles in life science research and drug discovery.”

“Life Technologies is committed to supporting growth of China’s biotech industry,” said Dr Siddhartha Kadia, Life Technologies President, Greater China. “We are delighted to partner with Sino Biological to distribute more than 6000 human-derived proteins and antibodies.”

Proteins and antibodies represent a fundamental tool employed by pharmaceutical researchers and academic scientists to facilitate the discovery of novel therapeutic targets in the process of drug development. Proteins and antibodies are also used to culture cells for basic research, drug discovery and production, and development of novel therapeutics such as stem cells. The agreement calls for joint development of proteomic products for additional applications including flow cytometry and imaging technologies.